Track Addex Therapeutics Ltd — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Addex Therapeutics Ltd ADXN Open Addex Therapeutics Ltd in new tab

6.83 USD
EPS
-9.22
P/B
0.91
ROE
-72.84
Beta
1.87
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 25, 2026
EPS-9.22
Book Value7.78
Price to Book0.91
Debt/Equity0.61
Growth
Revenue Growth-0.15%
Estimates
Forward P/E-142.00
Forward EPS-0.05

DCF Valuation

Tweak assumptions to recompute fair value for Addex Therapeutics Ltd (ADXN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Addex Therapeutics Ltd Logo Addex Therapeutics Ltd Analysis (ADXN)

Switzerland Health Care Official Website Stock

Is Addex Therapeutics Ltd a good investment? Addex Therapeutics Ltd (ADXN) is currently trading at 6.83 USD.

Earnings Schedule: Addex Therapeutics Ltd is expected to release its next earnings report on May 25, 2026. The market consensus estimate for Forward EPS is -0.05.

Investor FAQ

Does Addex Therapeutics Ltd pay a dividend?

No, it does not currently pay a dividend.

What asset class is Addex Therapeutics Ltd?

Addex Therapeutics Ltd is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 25, 2026. The company currently has a trailing EPS of -9.22.

Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Exchange Ticker
NMS (United States) ADXN

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion